Showing results (151-160 of 191) with videos related to
Sort By:
Pageof 20
The Journal of Urology|November 17, 1998
Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findingsJ I Epstein, D W Chan, L J Sokoll, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III diseaseD W Chan, R A Beveridge, H Muss, et al.Urology|April 18, 2001
Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancerM Han, S Piantadosi, M L Zahurak, et al.Clinical Chemistry|December 4, 1998
Analytical and clinical evaluation of an electrochemiluminescence immunoassay for the determination of CA 125H E van Ingen, D W Chan, W Hubl, et al.British Journal of Cancer|July 25, 2013
The interaction between C35 and ΔNp73 promotes chemo-resistance in ovarian cancer cellsT H-Y Leung, S C-S Wong, K K-L Chan, et al.JAMA|April 22, 1992
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate diseaseH B Carter, J D Pearson, E J Metter, et al.Urology|March 1, 1997
Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosisH B Carter, A W Partin, A A Luderer, et al.Hybridoma|January 8, 2000
Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassayT J Wang, H J Linton, J Payne, et al.The Journal of Urology|November 7, 2001
Plasma selenium level before diagnosis and the risk of prostate cancer developmentJ D Brooks, E J Metter, D W Chan, et al.Clinical Chemistry|October 1, 1988
Monitoring breast cancer with CA 549D W Chan, R A Beveridge, D J Bruzek, et al.Pageof 20